The biotech company iOmx, located in Martinsried/Munich, Germany, leverages its unique genetic screening platform, called iOTarg, to comprehensively discover novel immune-checkpoint targets in cancer cells that inhibit T cell’s ability to kill them.
TO THE COMPANY
Partner
Dr. Matthias Kromayer